Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.46 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4525177 | 1.00 | PREP (0.46) | PREPAADATGRIN2BKLK7KLK5 | |
| SCHEMBL204569 | 0.80 | AADAT (0.44) | PREPAADATKLK7KLK5TMEM97 | |
| SCHEMBL29277932 | 0.80 | PREP (0.52) | PREPAADATGRIN2BKLK7KLK5 | |
| SCHEMBL4220121 | 0.79 | PREP (0.50) | PREPAADATKLK7KLK5TMEM97 | |
| SCHEMBL10117812 | 0.79 | AADAT (0.46) | PREPAADATTMEM97SIGMAR1TSHR | |
| SCHEMBL3224486 | 0.79 | AADAT (0.46) | PREPAADATTMEM97SIGMAR1TSHR | |
| SCHEMBL3224476 | 0.79 | AADAT (0.46) | PREPAADATTMEM97SIGMAR1TSHR | |
| SCHEMBL8546518 | 0.78 | PTGIR (0.56) | PREPAADATKLK7KLK5TMEM97 | |
| SCHEMBL7490522 | 0.78 | PTGIR (0.56) | PREPAADATKLK7KLK5TMEM97 | |
| SCHEMBL7494762 | 0.78 | PTGIR (0.56) | PREPAADATKLK7KLK5TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372601-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3372601-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | PREP 4021/4885AADAT 1539/4885GRIN2B 382/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | PREP 3994/4885AADAT 1329/4885GRIN2B 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.